Bradykinin modulation of tumor vasculature: I. Activation of B2 receptors increases delivery of chemotherapeutic agents into solid peripheral tumors, enhancing their efficacy.
暂无分享,去创建一个
R. Bartus | D. Emerich | R. Dean | J. Marsh | P. Snodgrass | D. Lafreniere | T. Wiens | B. Hasler | M. Agostino | H. Xiong | M. Pink | B. Kim
[1] R. Bartus,et al. Bradykinin modulation of tumor vasculature: II. activation of nitric oxide and phospholipase A2/prostaglandin signaling pathways synergistically modifies vascular physiology and morphology to enhance delivery of chemotherapeutic agents to tumors. , 2001, The Journal of pharmacology and experimental therapeutics.
[2] K. Kinzler,et al. Genes expressed in human tumor endothelium. , 2000, Science.
[3] J. Cox,et al. The influence of hydralazine on the vasculature, blood perfusion and chemosensitivity of MAC tumours. , 1992, British Journal of Cancer.
[4] R K Jain,et al. Delivery of novel therapeutic agents in tumors: physiological barriers and strategies. , 1990, Journal of the National Cancer Institute.
[5] R. Bartus,et al. Enhanced delivery of carboplatin into brain tumours with intravenous CereportTM (RMP-7): dramatic differences and insight gained from dosing parameters , 1999, British Journal of Cancer.
[6] L. M. Leeb-Lundberg,et al. B2 kinin receptor-mediated internalization of bradykinin in DDT1 MF-2 smooth muscle cells is paralleled by sequestration of the occupied receptors. , 1993, Archives of biochemistry and biophysics.
[7] R K Jain,et al. Haemodynamic and transport barriers to the treatment of solid tumours. , 1991, International journal of radiation biology.
[8] K. Black,et al. Cyclic GMP-specific phosphodiesterase inhibition and intracarotid bradykinin infusion enhances permeability into brain tumors. , 1998, Cancer research.
[9] W. Gullick,et al. Bradykinin receptors undergo ligand-induced desensitization. , 1990, Biochemistry.
[10] G. Rosner,et al. Effects of bradykinin on the hemodynamics of tumor and granulating normal tissue microvasculature. , 1992, Radiation research.
[11] R. Bartus,et al. Pathway across blood-brain barrier opened by the bradykinin agonist, RMP-7 , 1995, Brain Research.
[12] R. Bartus,et al. Intravenous cereport (RMP-7) modifies topographic uptake profile of carboplatin within rat glioma and brain surrounding tumor, elevates platinum levels, and enhances survival. , 2000, The Journal of pharmacology and experimental therapeutics.
[13] R. Bartus,et al. Intravenous RMP-7 selectively increases uptake of carboplatin into rat brain tumors. , 1996, Cancer research.
[14] F. Yuan,et al. Transvascular drug delivery in solid tumors. , 1998, Seminars in radiation oncology.
[15] R. Bartus,et al. The Development of the Bradykinin Agonist Labradimil as a Means to Increase the Permeability of the Blood-Brain Barrier , 2001, Clinical pharmacokinetics.
[16] Bartus Rt. The blood-brain barrier as a target for pharmacological modulation. , 1999 .
[17] P. J. Elliott,et al. Controlled Modulation of BBB Permeability Using the Bradykinin Agonist, RMP-7 , 1996, Experimental Neurology.
[18] D. V. Hoff,et al. Cancer chemotherapy handbook , 1980 .
[19] K. Black,et al. Intracarotid infusion of RMP-7, a bradykinin analog: a method for selective drug delivery to brain tumors. , 1994, Journal of neurosurgery.
[20] J. Bascands,et al. In vivo and in vitro homologous desensitization of rat glomerular bradykinin B2 receptors. , 1995, European journal of pharmacology.
[21] R. Bartus,et al. Permeability of the blood brain barrier by the bradykinin agonist, RMP-7: evidence for a sensitive, auto-regulated, receptor-mediated system. , 1996, Immunopharmacology.
[22] J. Rosenbaum,et al. The mechanism for the rapid desensitization in bradykinin-stimulated inositol monophosphate production in NG108-15 cells involves interaction of a single receptor with multiple signaling pathways. , 1993, The Journal of pharmacology and experimental therapeutics.